PhD student Maddy Smith shares what she learned from attending a recent international conference on diabetes research.
An exciting time for metabolic health
Weight loss drugs such as Wegovy and Ozempic have made many headlines and sparked a frenzy on social media in recent months. Not only is their potential to “end obesity” being unpacked in the media, but also their issues such as side effects, weight regain after stopping taking it, and supply shortages. Since obesity is a main risk factor for type 2 diabetes, these new drugs have implications for diabetes treatment – in fact, some of them were originally developed to treat diabetes and weight loss was noticed to be a concurrent effect.
